Role of K(+) channels in the coronary and renal vascular reactivity to vasopressin in diabetic rats.
To study the role of K(+) channels in the coronary and renal vascular response to vasopressin during diabetes mellitus, and whether there are gender differences in this role, we have examined the isometric response to this peptide of 2-mm-long arterial segments from male and female, normoglycemic and streptozotocin-induced diabetic rats. Vasopressin (10(-12)-3 x 10(-8) M) produced arterial concentration-dependent contraction, and during normoglycemia, this contraction was lower in coronary arteries from female than from male rats, and it was similar in renal arteries from both genders. This contraction was reduced by diabetes in coronary arteries, and increased in renal arteries, from both genders. The blocker of Ca(2+)-sensitive K(+) channels charybdotoxin (10(-7) M) increased the contraction to vasopressin in coronary arteries of diabetic females, but not in the other cases (diabetic males and normoglycemic females or males). This blocker also increased the contraction to vasopressin in renal arteries from diabetic, but not in those from normoglycemic female rats, and also increased it in a higher magnitude in arteries from diabetic than in those from normoglycemic male rats. The blocker of ATP-sensitive K(+) channels glybenclamide (10(-5) M) or the scavenger of superoxide radicals superoxide dismutase (100 U/ml) did not modify the contraction to vasopressin in any experimental group. These results suggest that diabetes activates the modulatory role of K(+) channels in the coronary and renal vasoconstriction to vasopressin, but it alters in a different way the vasoconstriction to vasopressin in these two types of arteries. The effects of diabetes on this vasoconstriction are not related to increased release of superoxide radicals.
Sanz
Elena
E
Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma, Arzobispo Morcillo 2, 28029 Madrid, Spain.
Fernández
Nuria
N
Monge
Luis
L
Climent
Belén
B
Diéguez
Godofredo
G
García-Villalón
Angel Luis
AL
D000818:Animals; D001786:Blood Glucose; D018999:Charybdotoxin / Q000008:administration & dosage / Q000493:pharmacokinetics; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005905:Glyburide / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000503:physiopathology; D015221:Potassium Channels / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D017207:Rats, Sprague-Dawley; D012077:Renal Artery / Q000187:drug effects* / Q000503:physiopathology; D012727:Sex Characteristics; D013311:Streptozocin / Q000009:adverse effects; D014667:Vasopressins / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*
D001786:Blood Glucose; D015221:Potassium Channels; D014667:Vasopressins; D018999:Charybdotoxin; D013311:Streptozocin; D005905:Glyburide